Inhibikase Therapeutics Reports Results from Phase 2 201 Trial for Risvodetinib
On January 29, 2025, Inhibikase Therapeutics, Inc. (NYSE:IKT) disclosed findings from the Phase 2 201 trial (the “201 Trial”) evaluating risvodetinib, a selective inhibitor of non-receptor Abelson Tyrosine Kinases, in untreated Parkinson’s disease. The 201 Trial involved 126 individuals with untreated Parkinson’s disease who were, on average, 14 months post-diagnosis. Participants received doses of 50 […]
More Stories
Russia Bans Producers From Exporting Gasoline
By Guy Birchall Russia extended a temporary ban on gasoline exports to producers, Moscow said on April 2, citing the...
Who is Tiger Woods? Age, Marriage, Children, and Recent Controversy
Tiger Woods is one of the most famous American golfers. He is known as one of the greatest golf players...
Oil Falls, Stocks Jump on Renewed Hopes of Iran War Ending
By Tom Ozimek Oil prices dropped and stocks around the world rallied on April 1 on renewed hopes of a...
US Appeals Court Blocks Judge’s Rulings Against Trump Immigration Detention Policy
By Jack Phillips A U.S. appeals court on Tuesday halted a federal judge’s nationwide rulings that blocked the Trump administration...
Trump Says He’s Strongly Considering Pulling US Out of NATO
By Guy Birchall U.S. President Donald Trump said he is strongly considering withdrawing the United States from NATO, in comments...
Iran’s Top Leader Issues Statement Saying Regime Will Keep Backing Anti-Israel Forces
By Jack Phillips Iran’s top leader released a new statement on April 1 saying the Iranian regime will continue to...